Phase 3Active, not recruitingAge-related condition
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
- Sponsor
- Bristol-Myers Squibb (Industry)
- Enrollment
- 1,255 enrolled
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BMS-986278; BMS-986278 Placebo
- Ages
- adults, older adults
- Registry
- NCT06003426
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Primary outcomes
- Number of participants that experience spontaneous syncopal events
- Absolute change from baseline in forced vital capacity (FVC) measured in mL
History
Study completion expected
Primary completion
Last registry update
Started
Registered